Glenmark Pharmaceuticals Limited

rs,

vember 17, 2022 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001. Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E)

₹ 1,700

its journey over the last two decades…. Glenmark Group, two decades ago Consolidated revenues: ~ ₹ 1,700 mn1 Revenue contribution of ex-India markets: ~8% Manufacturing facilities: 2 (formulations) Glob

8%

, two decades ago Consolidated revenues: ~ ₹ 1,700 mn1 Revenue contribution of ex-India markets: ~8% Manufacturing facilities: 2 (formulations) Global employee base: ~1,000 Presence in API: No Pres

₹ 123,049

Glenmark Group, today Leading Integrated Research-led Global Consolidated revenues in FY22: ₹ 123,049 mn 14th largest1 and amongst the fastest growing in the Indian market 15th largest2 generic comp

10 million

neric company by prescriptions filled in the USA 5th largest3 Indian generic company in Europe ~10 million4 COVID patients globally prescribed with FabiFlu® (favipiravir) End-to-end R&D capabilities: API

55%

diversified formulations business built organically with commercial presence in 80+ countries ~55% contribution to revenue coming from branded markets5 Dermatology, Respiratory, Oncology: clear f

82.84%

th branded, generics, and OTC segments in therapy areas of Dermatology, Respiratory and Oncology (82.84% subsidiary) Focused on manufacturing and marketing of API products across all major markets glob

100%

sed on manufacturing and marketing of API products across all major markets globally (US based; 100% subsidiary) Innovation biotech company focused on development of novel biological molecules as po

22%

venue growth over next 4 years Continuous improvement in EBITDA margin Zero net debt by FY26 22% ROCE1,2 by FY27 Evaluate enhancing dividend pay-outs, share buybacks over the next 4 years 1. RO

rs 1

FY26 22% ROCE1,2 by FY27 Evaluate enhancing dividend pay-outs, share buybacks over the next 4 years 1. ROCE: Earnings Before Interest & Tax (EBIT) / Capital Employed 2. Capital Employed = Tangible Net

3 million

year 2025** Zero waste to landfill at all our plant locations by the year 2027 Aspire to impact 3 million lives by 2025 Deepen global presence and deliver quality affordable in new markets Continue focu

10 %

product transparency 4th Consecutive Year 1 of 4 Indian Pharma 1 of 15 Indian Companies Top 10 % ile Continuous score improvement * Covers Scope 1 and Scope 2 emissions only ** for GPL only (ex

“al GLENMARK INVESTOR DAY NOVEMBER 17, 2022 40 10-310-210-1100101102103-20020406080100120Antibody concentration (nM)CD47/SIRPa inhibition (%)anti-CD47 mAb (5F9)ISB 1442 ISB 1442 Only Binds to CD47 After Engaging CD38, Reducing Potential For On-Target, Off-Tumor Depletion of Red Blood Cells Reduced Binding to RBC Minimal RBC Depletion Statistics: 2-way ANOVA with multiple comparisons.”

Our Mission

1

Our Vision

1

Asset or BEAT Platform Deal Types

1

Other Studies

1

Presentation Time

1

Our Vision

We dare to imagine a world where cure is possible. GLENMARK INVESTOR DAY NOVEMBER 17, 2022 NOVEMBER 17, 2022 29 1 Proprietary BEAT ® Platform Development of Full-Length Multispecific Therapeutic Antibodies 2 Clinical-Stage Oncology Assets ISB 1342 (CD38xCD3) BEAT 1.0 Bispecific ISB 1442 (CD38xCD47) BEAT 2.0 Biparatopic Bispecific 2 Autoimmune Assets for Partnering ISB 880 IL-1RAP Antagonist in Phase 1, Licensed to Almirall in December 2021 Telazorlimab OX40 Antagonist Successfully Completed Phase 2b, Ongoing Discussions 220 Ichno-genius Experts in End-to-End Biotechnology Drug Development 3 Discovery-Stage Assets ISB 2001 (BCMAxCD38xCD3) Trispecific Antibody One Led by an Accomplished Leadership Team US and Switzerland Expansion to Solid Tumors with ISB 2004 and ISB 2005 More information on www.ichnossciences.com NOVEMBER 17, 2022 BEAT® Enables Production of Multispecific Antibodies with Competitive Developability Properties BEAT® 1.0 BEAT® 2.0 (2+1) TRISPECIFIC(TREAT™) Fab scFv ISB 13

Asset or BEAT Platform Deal Types

Co-development (shared costs) • Out-licensing • Global rights • Regional rights • Alliance Management For collaboration, email us at Partnership@IchnosSciences.com GLENMARK INVESTOR DAY NOVEMBER 17, 2022 34 Unmet Market Needs and Commercial Environment Multiple Myeloma Acute Myeloid Leukemia UNMET NEEDS Poor Outcome for Triple Refractory Patients1: • 31% Overall Response Rate with subsequent therapy • 9 months median Overall Survival • 3 months median Progression Free Survival • Patients may cycle through many combinations and classes of drugs over 10 or more years UNMET NEEDS • 2/3 patients will go into remission, but 1/2 will relapse2 • Options for 2L treatment are not viewed positively3 • No single standard therapy for relapsed/refractory patients • Few options in late-stage development for AML 1 Gandhi UH et al. Leukemia 2019; 33: 2266–75 2 American Cancer Society 3 Internal Assessment, Innovation Partners GLENMARK INVESTOR DAY NOVEMBER 17, 2022 35 ISB 1342 (CD38 x CD3) Bispecific

Other Studies

• Phase 2 combination studies • Phase 2 in other CD38-expressing hematologic malignancies Primary endpoint: ORR P h a s e 3 C o n f i r m a t o r y S t u d e s i GLENMARK INVESTOR DAY NOVEMBER 17, 2022 38 ISB 1442 Redirects Myeloid Cells to CD38+ Tumors and Overcomes Mechanisms of Resistance to Daratumumab ISB 1442 (CD38 x CD47) biparatopic bispecific antibody BEAT® 2.0 KEY ATTRIBUTES • Dual binding to CD38 and CD47 epitopes, increasing avidity relative to daratumumab • Two Fab regions drive binding to distinct CD38 epitopes that don’t compete functionally with daratumumab • One arm blocks CD47-SIRPa binding on tumor cells to enhance ADCP + Enhanced phagocytosis by blocking CD47 and increasing activation signaling through FcγR binding + CD47 is over-expressed by hematologic tumors and associated with a worse prognosis + Reduced potential for antigen sink with lower-affinity Fab binding to CD47 expressed on normal cells • Potent ADCC, CDC and ADCP based on optimized affinity, architectu

Presentation Time

5:00 PM Session Time: 4:00 PM - 5:30 PM Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (link) Sanjay Mohan, MD Poster Sunday 11 DEC 6:00 PM - 8:00 PM Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL (link) Stefano Sammicheli, PhD Poster Sunday 11 DEC 6:00 PM - 8:00 PM A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (link) Tony Jiang, MD, PhD Poster Monday 12 DEC 6:00 PM - 8:00 PM GLENMARK INVESTOR DAY NOVEMBER 17, 2022 44 Summary of Key Assets and Inflection Points Mechanism Target Indication(s) Market Size (2022)1 ISB 1342 ISB 1442 ISB 2001 CD38 X CD3 BEAT® BISPECIFIC ANTIBODY Multiple Myeloma CD38 X CD47 BEAT® BIPARATOPIC BISPECIFIC ANTIBODY Multiple Myeloma and Acute Myelo